Recent Company News

• 05:15 PM ET Apr 15, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 12:07 PM ET Apr 15, 2025
  

  BNP Paribas Exane initiates MRK.GR, NOVN.SW, NOVO.B.DC, others

• 01:53 PM ET Apr 11, 2025
  

  UCB announces findings from real-world evidence studies of romosozumab (€133.50, 0.00)

• 04:35 AM ET Apr 03, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 10:02 PM ET Apr 08, 2025
  

  Follow-up: US President Donald Trump says the US will unveil "major" tariff on imports of pharmaceutical goods - NBC News

• 08:51 AM ET Apr 07, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:38 PM ET Apr 04, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:22 PM ET Apr 04, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 6-Apr

• 11:46 AM ET Apr 01, 2025
  

  UCB's RYSTIGGO now approved for adults with Generalized myasthenia Gravis (gMG) in Canada (€163.50, 0.00)